Celltrion Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Hyong-Gi Kim

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	10.2yrs
CEO ownership	0.1%
Management average tenure	no data
Board average tenure	3.2yrs

Recent management updates

Recent updates

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

CEO

Hyong-Gi Kim (58 yo)

10.2yrs

Tenure

Mr. Hyong-Gi Kim serves as Chief Executive Officer at Celltrion, Inc. Mr. Kim served as Vice President of Celltrion Pharm Inc. He served as Head of Strategy and Planning Team, Daewoo Motor Company. He serv...

Board Members

Name	Position	Tenure	Compensation	Ownership
Hyong-Gi Kim	CEO & Internal Director	10.2yrs	no data	0.099% ₩ 38.9b
Woo-Sung Kee	CEO & Internal Director	10.2yrs	no data	0.089% ₩ 34.9b
Jin-seok Seo	Co-CEO & Inside Co-Chairman of the Board	3.2yrs	no data	no data
Jung-Jin Seo	Inside Co-Chairman of the Board	12.2yrs	no data	4% ₩ 1.6t
Soon-Woo Lee	Independent Director	2.2yrs	no data	no data
Byoung Jeon	Independent Outside Director	10.2yrs	no data	no data
Jong Lee	Independent Outside Director	9.4yrs	no data	no data
Byung-oh Kwon	Director	no data	no data	0.00087% ₩ 340.8m
Keun-young Kim	Independent Director	2.2yrs	no data	no data
Young-hyeh Ko	Independent Director	2.2yrs	no data	no data
Jae-sik Lee	Independent Director	2.2yrs	no data	no data
Dae-hyun Yoo	Independent Director	2.2yrs	no data	no data

3.2yrs

Average Tenure

66yo

Average Age

Experienced Board: A068270's board of directors are considered experienced (3.2 years average tenure).

Celltrion Management

Management criteria checks 1/4

Key information

Recent management updates

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Recent updates

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Celltrion, Inc. (KOSE:A068270) completed the acquisition of portfolio of select non-core otc and prescription pharmaceutical products exclusively in Asia Pacific from Takeda Pharmaceutical Company Limited (TSE:4502).

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

New 90-day high: ₩330,000

Celltrion Presents Efficacy and Safety Data for Potential Covid-19 Treatment Candidate Ct-P59 in Patients with Mild Symptoms

New 90-day low: ₩245,500

New 90-day low: ₩278,500

Price target raised to ₩284,353

CEO

Tenure

Board Members

Average Tenure

Average Age